Paronychia

Summary

Paronychia (MONDO:0005898) is a disease and 8 clinical trials. Top therapeutic interventions include timolol, betamethasone valerate, and fluconazole. A subtype of nail disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	paronychia
Mondo ID	MONDO:0005898
EFO	EFO:0007421
MeSH	D010304
DOID	DOID:13117
NCIT	C79702
SNOMED CT	71906005
UMLS	C0030578
MedGen	45334
Is cancer (heuristic)	no

Also known as: paronychia · paronychia (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of nail disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › nail disorder › paronychia

Related subtypes (6): nail tumor, nail anomaly, inherited isolated nail anomaly, Basaran Yilmaz syndrome, Judge Misch wright syndrome, nail infection

Subtypes (1): herpetic whitlow

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Betamethasone Valerate	Phase 3 (in late-stage trials)
Timolol	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	3
Not specified	3
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02464826	PHASE4	COMPLETED	A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment
NCT06643416	PHASE3	RECRUITING	Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
NCT07311759	PHASE3	ACTIVE_NOT_RECRUITING	Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.
NCT06140186	PHASE3	UNKNOWN	Efficacy and Safety of Timolol for TKI Induced Paronychia
NCT05639933	PHASE2	RECRUITING	Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
NCT03908892	Not specified	UNKNOWN	Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib
NCT05165082	Not specified	COMPLETED	The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study
NCT06411093	Not specified	COMPLETED	Efficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor Inhibitors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TIMOLOL	4	7
BETAMETHASONE VALERATE	4	2
FLUCONAZOLE	4	1
MOMETASONE FUROATE	4	1
TETRACYCLINE	4	1
CHEMBL1744069	0	2